Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.

Oncotarget - 11 Oct 2016

Huang Chu-Ying, Wang Li, Feng Cheng-Jun, Yu Ping, Cai Xiao-Hong, Yao Wen-Xiu, Xu Yong, Liu Xiao-Ke, Zhu Wen-Jiang, Wang Yan, Zhou Jin, Lu You, Wang Yong-Sheng

Abstract excerpt

BACKGROUND: Bisphosphonates have exhibited anti-tumor activity in non-small cell lung cancer (NSCLC). We aimed to evaluate whether the combination of bisphosphonates with tyrosine kinase inhibitors of EGFR (EGFR-TKIs) could obtain a synergistic effect on advanced NSCLC patients with EGFR mutations. METHODS: Between January 2008 and October 2013, 114 advanced EGFR mutations NSCLC patients who received EGFR-TKIs as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Neoplasms
Share to Crown Ethers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diphosphonates

Share to Disease-Free Survival

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Imidazoles

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 26624882
DOI: 10.18632/oncotarget.5515
PMCID: PMC5341815

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.PMID 26624882Read ↗

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases.Semantic proximity Read ↗

Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy.Semantic proximity Read ↗

Prognosis of different bone metastases patterns in EGFR-mutant advanced lung adenocarcinoma patientsSemantic proximity Read ↗

Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment.Semantic proximity Read ↗

Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs.Semantic proximity Read ↗

Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.Semantic proximity Read ↗

[Predictive relevance of KRAS mutational status in bone metastatic lung adenocarcinoma treated with bisphosphonate therapy].Semantic proximity Read ↗

Radiotherapy effects on brain/bone metastatic adenocarcinoma lung cancer and the importance of EGFR mutation test.Semantic proximity Read ↗

Prognostic role of targeted therapy in patients with multiple-site metastases from non-small- cell lung cancer.Semantic proximity Read ↗

Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancer: a retrospective, multicenter studySemantic proximity Read ↗

A case of lung adenocarcinoma with postoperative recurrence of multiple bone metastases that showed a gradual complete response to combined administration of erlotinib and zoledronic acid.Semantic proximity Read ↗

Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.